Telomir Pharmaceuticals, Number Of Shares Shorted vs. Market Capitalization
| TELO Stock | 4.91 0.03 0.61% |
For Telomir Pharmaceuticals, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telomir Pharmaceuticals, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telomir Pharmaceuticals, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telomir Pharmaceuticals,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telomir Pharmaceuticals, Common over time as well as its relative position and ranking within its peers.
Telomir |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.78) | Return On Assets (2.05) | Return On Equity (17.53) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Telomir Pharmaceuticals, Market Capitalization vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Telomir Pharmaceuticals,'s current stock value. Our valuation model uses many indicators to compare Telomir Pharmaceuticals, value to that of its competitors to determine the firm's financial worth. Telomir Pharmaceuticals, Common is rated fifth in number of shares shorted category among its peers. It is rated below average in market capitalization category among its peers creating about 225.91 of Market Capitalization per Number Of Shares Shorted. At this time, Telomir Pharmaceuticals,'s Market Cap is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telomir Pharmaceuticals,'s earnings, one of the primary drivers of an investment's value.Telomir Market Capitalization vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Telomir Pharmaceuticals, |
| = | 650.6 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Telomir Pharmaceuticals, |
| = | 146.98 M |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Telomir Market Capitalization vs Competition
Telomir Pharmaceuticals, Common is rated below average in market capitalization category among its peers. Market capitalization of Health Care industry is at this time estimated at about 80.82 Billion. Telomir Pharmaceuticals, adds roughly 146.98 Million in market capitalization claiming only tiny portion of equities under Health Care industry.
Telomir Pharmaceuticals, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Telomir Pharmaceuticals,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telomir Pharmaceuticals, will eventually generate negative long term returns. The profitability progress is the general direction of Telomir Pharmaceuticals,'s change in net profit over the period of time. It can combine multiple indicators of Telomir Pharmaceuticals,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -49.5 K | -52 K | |
| Operating Income | -3.5 M | -3.4 M | |
| Net Loss | -11.8 M | -11.2 M | |
| Income Before Tax | -11.8 M | -11.2 M | |
| Total Other Income Expense Net | -8.2 M | -7.8 M | |
| Net Loss | -11.8 M | -11.2 M | |
| Income Tax Expense | -2.1 M | -2 M | |
| Net Interest Income | -1.5 M | -1.4 M | |
| Net Loss | (0.44) | (0.42) | |
| Income Quality | 0.30 | 0.28 |
Telomir Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Telomir Pharmaceuticals,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telomir Pharmaceuticals, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telomir Pharmaceuticals,'s important profitability drivers and their relationship over time.
Use Telomir Pharmaceuticals, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telomir Pharmaceuticals, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will appreciate offsetting losses from the drop in the long position's value.Telomir Pharmaceuticals, Pair Trading
Telomir Pharmaceuticals, Common Pair Trading Analysis
The ability to find closely correlated positions to Telomir Pharmaceuticals, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telomir Pharmaceuticals, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telomir Pharmaceuticals, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telomir Pharmaceuticals, Common to buy it.
The correlation of Telomir Pharmaceuticals, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telomir Pharmaceuticals, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telomir Pharmaceuticals, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telomir Pharmaceuticals, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Telomir Pharmaceuticals, position
In addition to having Telomir Pharmaceuticals, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SPAC Thematic Idea Now
SPAC
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
To fully project Telomir Pharmaceuticals,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Telomir Pharmaceuticals, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Telomir Pharmaceuticals,'s income statement, its balance sheet, and the statement of cash flows.